WallStSmart

Boston Scientific Corp (BSX)vsIntelligent Bio Solutions Inc. (INBS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Boston Scientific Corp generates 526668% more annual revenue ($20.61B vs $3.91M). BSX leads profitability with a 17.3% profit margin vs -296.8%. BSX earns a higher WallStSmart Score of 76/100 (B+).

BSX

Strong Buy

76

out of 100

Grade: B+

Growth: 8.0Profit: 7.0Value: 5.3Quality: 6.5
Piotroski: 5/9Altman Z: 1.78

INBS

Hold

38

out of 100

Grade: F

Growth: 6.3Profit: 2.0Value: 4.0Quality: 6.0
Piotroski: 2/9Altman Z: -14.28
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BSXSignificantly Overvalued (-17.8%)

Margin of Safety

-17.8%

Fair Value

$37.37

Current Price

$43.19

$5.82 premium

UndervaluedFair: $37.37Overvalued
INBSSignificantly Overvalued (-26.5%)

Margin of Safety

-26.5%

Fair Value

$4.15

Current Price

$1.97

$2.18 premium

UndervaluedFair: $4.15Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BSX5 strengths · Avg: 8.6/10
EPS GrowthGrowth
100.0%10/10

Earnings expanding 100.0% YoY

Market CapQuality
$66.87B9/10

Large-cap with strong market position

PEG RatioValuation
0.548/10

Growing faster than its price suggests

Price/BookValuation
2.5x8/10

Reasonable price relative to book value

Operating MarginProfitability
20.6%8/10

Strong operational efficiency at 20.6%

INBS3 strengths · Avg: 9.7/10
Price/BookValuation
0.4x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
45.5%10/10

Revenue surging 45.5% year-over-year

Debt/EquityHealth
0.219/10

Conservative balance sheet, low leverage

Areas to Watch

BSX1 concerns · Avg: 4.0/10
Altman Z-ScoreHealth
1.784/10

Distress zone — elevated risk

INBS4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$5.50M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Return on EquityProfitability
-170.2%2/10

ROE of -170.2% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : BSX

The strongest argument for BSX centers on EPS Growth, Market Cap, PEG Ratio. Profitability is solid with margins at 17.3% and operating margin at 20.6%. Revenue growth of 11.6% demonstrates continued momentum.

Bull Case : INBS

The strongest argument for INBS centers on Price/Book, Revenue Growth, Debt/Equity. Revenue growth of 45.5% demonstrates continued momentum.

Bear Case : BSX

The primary concerns for BSX are Altman Z-Score.

Bear Case : INBS

The primary concerns for INBS are EPS Growth, Market Cap, Piotroski F-Score.

Key Dynamics to Monitor

BSX profiles as a mature stock while INBS is a hypergrowth play — different risk/reward profiles.

INBS carries more volatility with a beta of 4.17 — expect wider price swings.

INBS is growing revenue faster at 45.5% — sustainability is the question.

BSX generates stronger free cash flow (171M), providing more financial flexibility.

Bottom Line

BSX scores higher overall (76/100 vs 38/100), backed by strong 17.3% margins and 11.6% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Boston Scientific Corp

HEALTHCARE · MEDICAL DEVICES · USA

Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.

Intelligent Bio Solutions Inc.

HEALTHCARE · MEDICAL DEVICES · USA

Intelligent Bio Solutions Inc. (INBS) is a cutting-edge biotechnology company focused on pioneering advanced diagnostic solutions and biomarker-driven technologies specifically designed for drug abuse testing and monitoring. By leveraging innovative scientific methodologies, INBS provides rapid and precise testing options that facilitate timely clinical decision-making and enhance patient outcomes. As the healthcare landscape increasingly demands sophisticated diagnostic tools, INBS is well-positioned to spearhead advancements in healthcare diagnostics, reaffirming its dedication to elevating healthcare quality and operational efficiency.

Want to dig deeper into these stocks?